ABSTRACT: Pazopanib and axitinib are ATP-competitive inhibitors of the vascular endothelial growth factor receptor. They have shown to be effective and tolerable treatment options for patients with metastatic renal cell cancer and therefore have been used for the control of this disease. Sorafenib is a kinase inhibitor drug approved for the treatment of primary kidney cancer, advanced primary liver cancer, and radioactive iodine resistant advanced thyroid carcinoma. Global energy, binding sites and molecular interactions between pazopanib, sorafenib and axitinib anticancer drugs with vascular endothelial growth factor (VEGF) was probed to find the best binding energy. The structures of pazopanib, axitinib and sorafenib were drawn and constructed using window based program of Arguslab and ACDlab ChemSketch softwares. Docking studies were performed using the Patch dock and Firedock online software packages. The protein data bank (PDB) files of the crystal structure of VEGF were subjected to refinement protocols. The interactive docking method was carried out for all the conformers of each compound in the selected active site. The docked compound was assigned a score according to its fit in the ligand binding pocket (LBP) and its binding mode. The docked complexes were interpreted using Molecular Molegro viewer software. The best binding energy (minimum energy) is -19.15 Kcal/mol, -22.48 Kcal/mol and -22.37 Kcal/mol for pozapanib, sorafenib and axitinid respectively. The negative value of the binding energy shows that pozapanib, sorafenib and axitinib can selectively inhibit VEGF.
INTRODUCTION
Pazopanib (trade name Votrient) is a potent and selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. It has been approved for renal cell carcinoma and soft tissue sarcoma by numerous regulatory administrations worldwide (Khurana et al., 2014; Verweij et al., 2013; Schöffski et al., 2012; Pick et al., 2012) . It is a multikinase inhibitor and VEGFR being amongst the inhibited enzymes (Zivi et al., 2012) . Laboratory anomalies include increased aspartate amino transferase, alanine aminotransferase and protein in the urine, oedema, hair loss or discolouration, taste changes, abdominal pain, hypertension, rash, fatigue and myelosuppression. Leucopenia, neutropenia, thrombocytopenia and lymhpoenia are also seen (Product Information Votrien, 2013) . Axitinib (AG013736; trade name Inlyta) is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models (Wilmes et al., 2007) and has shown partial responses in clinical trials with renal cell carcinoma (RCC) (Rini et al., 2005) and several other tumour types (Rugo et al., 2005) . Its primary mechanism of action is thought to be Vascular Endothelial Growth Factor receptor 1-3, c-KIT and PDGFR inhibition. This in turn enables it to inhibit angiogenesis (the formation of new blood vessels by tumours) (Escudier et al., 2007) . Sorafenib (FDA Approves Nexavar 2007 ) is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), and radioactive iodine resistant advanced thyroid carcinoma. Sorafenid is a small inhibitor of several tyrosine protien kinase, such as VEGFR, PDGFR and Raf family kinases (Nexavar dosing, 2013; Smalley et al., 2008; Keating and Santoro, 2009 ). At the current time sorafenib is indicated as a treatment for advanced renal cell carcinoma (RCC), unresectable hepatocellular carcinomas (HCC) and thyriod cancer (FDA Approves Nexavar, 2007; Nexavar dosing, 2013) . This study is designed to search the active sites, global energy and molecular interactions between pazopanib, axitinib and sorafenib anticancer drugs with VEGF. Chemical structures of pazopanib, axitinib and sorafenib are shown in Figure 1 .
MATERIALS AND METHODS
The structures of pazopanib, axitinib and sorafenib were drawn and constructed using window based program of Arguslab (Thompson et al., 2007) and ACDlab ChemSketch (Advanced Chemistry Develoment, 2008) softwares. Docking studies were performed using the Patch dock and firedock online software packages (Mashiach et al., 2008; Andrusier et al., 2007) . The protein data bank (PDB) files of the crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A (Mashiach et al., 2008) resolution having PDB entry number 2VPF was downloaded from the protein data bank website. Regularization and optimization for protein and ligand were performed and the protein structure was subjected to a refinement protocol using Molegro Molecular viewer (Molegro Molecular Viewer, 2012) .
Determination of the essential amino acid in binding site was carried out. The interactive docking method was carried out for all the conformers of each compound in the selected active site. The docked compound was assigned a score according to its fit in the ligand binding pocket (LBP) and its binding mode. The docked complexes were interpreted using Molecular Molegro viewer software (Molegro Molecular Viewer, 2012).
RESULTS AND DISCUSSION
The crystal structure of VEGF refined to 1.93 A resolution is shown in Figure 2 respectively. Global energy predictions for pozapanib, sorafenib and axitinib with VEGF complex were reported in Tables 1, 2 (Table 1) shown that the docking score ranked according to their global energy. The contributions of the van der Waals forces and atomic contact energy (ACE) to the global binding energy have been shown. The best binding energy (minimum energy) is -19.15 Kcal/mol. The negative value of the binding energy shows that the pozapanib can selectively inhibit VEGF. This is consistent with the work of Yadav et al. (2017) .
Sorafenib docked with VEGF is shown in Figure 4a .
Hydrogen bonding and steric interactions were observed in sorafenib ligand map (Figure 4b ). Hydrogen bonding occurred with HOH 177(F), HOH 140(F), HOH 166(F), Lys 107(F), HOH 202(E), HOH 114(F), HOH 140(E), and HOH 143(E). The strength of the bonds are -2.50, -0.01, -1.16, -0.56, -1.71, -1.26, -2.50 and -1.89 Kcal/mol respectively. These interactions were quite favorable due to negative free energy and suitable bond lengths. Steric interactions occurred with Thr 31(E), Thr 31(F) and Gln 89(H). Global energy predictions for Sorafenib -VEGF complex (Table 2) shown that the docking score has been ranked according to their global energy. The global energy is the binding energy of the solution. The contributions of the van der Waals forces and atomic contact energy (ACE) to the global binding energy is shown in Table 2 . The best binding energy (minimum energy) is -22.48 Kcal/mol. The negative value of the binding energy shows that the Sorafenib can selectively inhibit VEGF. This agreed with the report of Ahuja and Singh (2016) on in silico approach for SAR analysis of the predicted model of DEPDC1B: a vovel target for oral cancer. Axitinib docked with VEGF is shown in Figure 5a . (Table 3) showed the docking score. The contributions of the van der Waals forces and atomic contact energy (ACE) to the global binding energy have been presented in Table 3 . The best binding energy (minimum energy) is -22.37 Kcal/mol. The negative value of the binding energy shows that the axitinib can selectively inhibit VEGF. This is consistent with our previous publication using Patchdock, a molecular docking algorithm based on shape complementarity principles (Ikpeazu et al., 2017) 
Conclusion
The best binding energy (minimum energy) is -19.15 Kcal/mol, -22.48 Kcal/mol and -22.37 Kcal/mol for pozapanib, sorafenib and axitinib respectively. The negative value of the binding energy shows that pozapanib, sorafenib and axitinib can selectively inhibit VEGF. Molecular interaction was used in structure-based drug design to predict the binding energy and conformation of ligands complexed to target receptors. Molecular interaction can be seen as "lock-and key" theory of enzyme action. The receptor is seen as the lock while the ligand is the key. It tries to explain the best conformation of the ligand when it binds to the receptor. During molecular interaction, the ligand and the protein try to achieve the "best-fit".
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